rencofilstat

Rencofilstat is a novel, orally administered small molecule cyclophilin inhibitor developed primarily for the treatment of nonalcoholic steatohepatitis (NASH) and liver diseases associated with viral hepatitis. It binds to cyclophilin isomerase enzymes—specifically Cyclophilin A, B, and D—blocking their function with high potency. This inhibition reduces inflammatory cell infiltration, suppresses collagen synthesis and fibrosis by targeting Cyclophilin B, decreases pro-inflammatory signaling via Cyclophilin A/CD147 interaction blockade, and protects against cell death by inhibiting Cyclophilin D-mediated mitochondrial pore opening. Rencofilstat has demonstrated antifibrotic effects in preclinical models and early clinical trials for NASH, as well as antiviral activity against hepatitis B virus (HBV) through multiple mechanisms including blocking viral uptake and replication. The drug accumulates preferentially in the liver and has shown an excellent safety profile to date[1][2][5][6][8].

Other names

rencofilstat